Xbrane Biopharma AB Net Asset Quality Index
Xbrane Biopharma AB net asset quality index. Xbrane Biopharma AB (XBRANE) has a Net Asset Quality Index of 83.9% as of June 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of Skr642.61 Million minus total liabilities of Skr103.76 Million yields net assets of Skr538.85 Million. A higher index indicates a stronger, lower-leverage balance sheet. See shareholders equity of Xbrane Biopharma AB for net asset value and shareholders' equity analysis.
Quality Index
Net Assets
Total Assets
Total Liabilities
Net Asset Quality Index of Xbrane Biopharma AB (2012–2025)
Net asset quality index of Xbrane Biopharma AB from 2012 to 2025. This chart shows how Xbrane Biopharma AB's Net Asset Quality Index has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the index stands at 83.9%, representing net assets of Skr538.85 Million against total assets of Skr642.61 Million SEK. Check how strategically is Xbrane Biopharma AB's equity deployed to assess the company's strategic physical and investment asset allocation.
Xbrane Biopharma AB Net Asset Quality Index by Year (2012–2025)
Xbrane Biopharma AB net asset quality index by year from 2012 to 2025. The table below presents the year-by-year Net Asset Quality Index for Xbrane Biopharma AB from 2012 to 2025, covering 14 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For live market cap and overall valuation, see Xbrane Biopharma AB (XBRANE) market capitalisation.
| Year | Quality Index | Net Assets (SEK) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 83.5% | Skr560.65 Million | Skr671.62 Million | Skr110.97 Million | ▲ +58.7 pp |
| 2024 | 24.8% | Skr208.54 Million | Skr842.43 Million | Skr633.89 Million | ▼ -1.5 pp |
| 2023 | 26.2% | Skr171.34 Million | Skr653.51 Million | Skr482.17 Million | ▼ -35.3 pp |
| 2022 | 61.5% | Skr424.89 Million | Skr690.51 Million | Skr265.63 Million | ▼ -1.2 pp |
| 2021 | 62.7% | Skr431.74 Million | Skr688.43 Million | Skr256.69 Million | ▲ +7.1 pp |
| 2020 | 55.6% | Skr257.71 Million | Skr463.76 Million | Skr206.06 Million | ▲ +1.2 pp |
| 2019 | 54.4% | Skr184.32 Million | Skr338.94 Million | Skr154.62 Million | ▲ +21.5 pp |
| 2018 | 32.8% | Skr83.07 Million | Skr252.88 Million | Skr169.81 Million | ▼ -46.8 pp |
| 2017 | 79.7% | Skr88.41 Million | Skr110.96 Million | Skr22.55 Million | ▼ -11.2 pp |
| 2016 | 90.8% | Skr107.30 Million | Skr118.11 Million | Skr10.81 Million | ▲ +27.8 pp |
| 2015 | 63.1% | Skr47.51 Million | Skr75.33 Million | Skr27.82 Million | ▼ -31.1 pp |
| 2014 | 94.2% | Skr6.30 Million | Skr6.69 Million | Skr390.70K | ▼ -0.3 pp |
| 2013 | 94.5% | Skr8.69 Million | Skr9.20 Million | Skr505.44K | ▲ +81.1 pp |
| 2012 | 13.4% | Skr88.11K | Skr657.01K | Skr568.90K | — |